Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy
|ClinicalTrials.gov Identifier: NCT01169363|
Recruitment Status : Completed
First Posted : July 26, 2010
Last Update Posted : May 17, 2017
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is studying biomarkers in bone marrow and blood samples from older patients with acute myeloid leukemia treated with cytarabine-based therapy.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: proteomic profiling Other: flow cytometry Other: laboratory biomarker analysis|
- To validate a pre-specified proteomic classifier to predict the likelihood of complete response (CR) to cytarabine-based induction chemotherapy in older patients with non-M3 acute myeloid leukemia.
- To identify signaling nodes associated with risk of relapse among these patients who achieve a CR to induction chemotherapy.
OUTLINE: This is a multicenter study.
Previously collected bone marrow and peripheral blood samples are analyzed to validate the association of a pre-specified proteomic signature with clinical response via flow cytometry.
|Study Type :||Observational|
|Actual Enrollment :||200 participants|
|Official Title:||Validation of AML Proteomic Signature Associated With Clinical Response to Ara-C Based Induction Therapy in Patients 60 Years of Age or Older Using Samples From ECOG Studies 3999, 3993 and 1490|
|Actual Study Start Date :||July 8, 2010|
|Primary Completion Date :||August 8, 2010|
|Study Completion Date :||August 8, 2010|
- Proportion of patients achieving a complete response to induction chemotherapy [ Time Frame: 1 month ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01169363
|Principal Investigator:||Elisabeth Paietta, PhD||Our Lady of Mercy Medical Center|